证券时报·数据宝统计，巨子生物在港交所公告显示，12月23日以每股35.740港元至36.480港元的价格回 购40.00万股，回购金额达1439.66万港元。该股当日收盘价35.740港元，下跌0.89%，全天成交额2.08亿 港元。 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.23 | 40.00 | 36.480 | 35.740 | 1439.66 | | 2025.12.22 | 40.00 | 36.340 | 35.860 | 1442.97 | | 2025.12.19 | 40.00 | 35.520 | 34.540 | 1405.36 | | 2025.12.18 | 40.00 | 35.040 | 34.420 | 1388.30 | | 2025.12.17 | 40.00 | 35.220 | 34.620 | 1397.13 | | 2025.12.16 | 40.00 | 35.400 | 34.680 | 1402.61 | | ...

Group 1 - The company, Giant Bio (02367.HK), announced a share buyback on December 23, 2023, spending HKD 14.3966 million to repurchase 400,000 shares [1] - The buyback price per share ranged from HKD 35.74 to HKD 36.48 [1]

Group 1 - The company, Giant Bio (02367), announced a share buyback plan, committing to repurchase 400,000 shares at a cost of HKD 14.3966 million [1] - The buyback is scheduled to take place on December 23, 2025 [1] - This move indicates the company's strategy to enhance shareholder value through share repurchase [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事 ...

Group 1 - The core viewpoint of the report is that the rating of Giant Bio (02367) has been downgraded from "Buy" to "Neutral," with the target price reduced by 45% from HKD 64 to HKD 35 [1] - The company is facing multiple challenges, including a series of reputation crises and a double-digit decline in its core brand, Kefu Mei, during the Double Eleven shopping festival [1] - The report suggests that the investment logic for Giant Bio has shifted from growth to strategic adjustment, indicating a lack of clear catalysts for a rebound [1] Group 2 - The brokerage firm has lowered its revenue forecasts for 2025-2027 by an average of 30% to reflect the latest guidance from management and a more cautious outlook for 2026 [1] - The sales expense ratio forecast has been increased from 36% to 38% to account for execution challenges during the adjustment phase [1] - The target price is now based on a reduced price-to-earnings ratio of 16 times the 2026 forecast, down from the previous 21.5 times [1]

招商证券国际发布研报称，将巨子生物(02367)评级由"增持"下调至"中性"，将目标价从64港元下调45% 至35港元。报告指，公司正面临诸多挑战，包括一系列声誉危机，以及核心品牌可复美在双11大促期间 出现两位数下滑。虽然该行认为公司股价已基本消化相关问题及随后下调2025年销售指引，但该行对 2026年前景仍持谨慎态度。该行认为，当前市场一致预期可能过于乐观。 该行指，巨子生物的投资逻辑已由增长转向战略调整，该行认为当前尚缺乏明显的反弹催化剂。在企稳 迹象更加明朗之前，持观望态度。该行将2025-27年收入预测平均下调30%，以反映管理层最新指引及 该行对2026年更加审慎的展望。该行将销售费用率预测从36%上调至38%，以反映调整阶段下的执行挑 战。目标价基于由原来的2026年预测市盈率21.5倍降至16倍。 ...

Group 1 - The article reports on share buybacks conducted by various companies on December 22, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 1.035 million shares for a total of 636 million yuan, representing 1.052% of its total share capital for the year [2] - Other notable companies involved in the buyback include Xiaomi Group (01810), which repurchased 3.75 million shares for 149 million yuan, and China COSCO Shipping Holdings (01919), which repurchased 4.15 million shares for approximately 56.6 million yuan [2] Group 2 - The total number of shares repurchased by various companies varies significantly, with some companies like Huohai Biotechnology (06826) and Juzhi Biotechnology (02367) showing higher percentages of their total share capital repurchased [3] - For instance, Huohai Biotechnology repurchased 17,000 shares, accounting for 6.429% of its total share capital, while Juzhi Biotechnology repurchased 400,000 shares, representing 0.373% of its total [3] - The data indicates a trend of companies engaging in share buybacks as a strategy to enhance shareholder value and potentially stabilize stock prices during uncertain market conditions [1][2]

Core Viewpoint - The company, Giant Bio (02367.HK), has been actively repurchasing its shares, indicating a potential confidence in its stock value and a strategy to enhance shareholder value through buybacks [1] Group 1: Share Buyback Details - On December 22, the company repurchased 400,000 shares at a price range of HKD 35.860 to HKD 36.340, totaling HKD 14.4297 million [1] - The stock closed at HKD 36.060 on the same day, reflecting a 1.63% increase, with a total trading volume of HKD 192 million [1] - Since December 9, the company has conducted buybacks for 10 consecutive days, accumulating a total of 4 million shares repurchased at a total cost of HKD 141 million [1] Group 2: Historical Buyback Data - The buyback details for the past days are as follows: - December 19: 40,000 shares at a maximum price of HKD 35.520 and a total cost of HKD 14.0536 million [1] - December 18: 40,000 shares at a maximum price of HKD 35.040 and a total cost of HKD 13.8830 million [1] - December 17: 40,000 shares at a maximum price of HKD 35.220 and a total cost of HKD 13.9713 million [1] - December 16: 40,000 shares at a maximum price of HKD 35.400 and a total cost of HKD 14.0261 million [1] - December 15: 40,000 shares at a maximum price of HKD 35.240 and a total cost of HKD 13.9173 million [1] - December 12: 40,000 shares at a maximum price of HKD 35.220 and a total cost of HKD 14.0364 million [1] - December 11: 40,000 shares at a maximum price of HKD 35.360 and a total cost of HKD 13.8876 million [1] - December 10: 40,000 shares at a maximum price of HKD 36.220 and a total cost of HKD 14.3824 million [1] - December 9: 40,000 shares at a maximum price of HKD 36.180 and a total cost of HKD 14.3764 million [1]

Company News - Vanke Enterprise (02202.HK) has extended the grace period for the principal and interest payment of its fourth tranche of medium-term notes (total principal of 2 billion yuan) to 30 trading days [1] - Cathay Pacific Airways (00293) reported a passenger count of 2.5304 million in November, representing a year-on-year increase of 26% [1] - Shandong High New Energy (01250.HK) announced that its subsidiary Wuxiang Beiqing Smart Energy has signed an EPC contract with China Railway 17th Bureau, with a total contract value of 405.5 million yuan [1] - China General Nuclear Power (01816) reported that the commissioning of Units 1 and 2 in Huizhou has been adjusted, with expected operational dates moved to the first half and second half of 2026, respectively [1] Strategic Partnerships - Lehua Entertainment (02306.HK) has signed a business cooperation framework agreement with Youku Information Technology and Youku for 2026 [2] - Xinbao Global Holdings (00723.HK) has entered into a cooperation agreement with Guangxi Fenglin (601996.SH) to jointly develop the EU wood board and related product market [2] - Dipo Technology (01384.HK) has established a strategic cooperation agreement with Muxi Co., aiming to deepen collaboration in enterprise-level large model AI applications across key industries such as manufacturing, commercial circulation, transportation, and healthcare [2] Product Development - He Yu-B (02256.HK) announced that its CSF-1R inhibitor Beijiemai® has received approval from China's NMPA [3] - Saint Noble Pharmaceuticals-B (02257.HK) has completed Phase I trials for its investigational drug STP707 and has formally submitted the clinical research report to the FDA [4] - Nanshan Aluminum International (02610.HK) has increased its annual production capacity for alumina to 4 million tons [5] Share Buybacks - Tencent Holdings (00700.HK) repurchased 1.035 million shares at a cost of 636 million HKD, with repurchase prices ranging from 610.5 to 620 HKD [8] - Xiaomi Group-W (01810.HK) spent approximately 149 million HKD to repurchase 3.75 million shares, with prices between 37.61 and 42.50 HKD [9] - Giant Bio (02367.HK) repurchased approximately 14.43 million HKD worth of 400,000 shares, with prices between 34.71 and 36.34 HKD [10]

Group 1 - The company, Giant Bio (02367.HK), announced a share buyback on December 22, spending HKD 14.43 million to repurchase 400,000 shares [1]